Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial

Tjärnlund, Anna; Tang, Qingqin; Wick, Cecilia; Dastmalchi, Maryam; Mann, Heřman; Studýnková, Jana Tomasová; Chura, Radka; Gullick, Nicola; Salerno, Rosaria; Rönnelid, Johan; Alexanderson, Helene; Lindroos, Eva; Aggarwal, Rohit; Gordon, Patrick; Vencovský, Jiří; Lundberg, Ingrid E.

doi:10.1136/annrheumdis-2017-211751

Cited by 115 publications

(80 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tjärnlund et al (2018) was a randomized trial using intravenous abatacept either as an immediate start or a 3-month delayed start for patients with refractory dermatomyositis or polymyositis. 4 After 6 months of treatment, 47% of patients overall had met the study's definition of improvement. It was noted however, that four mild and four moderate adverse events were caused by the drug.…”

Section: Related Literaturementioning

confidence: 99%

Intravenous immunoglobulin is a treatment option for refractory dermatomyositis in adult patients

Clapp

2018

Clin. Res. Pract.

View full text Add to dashboard Cite

show abstract

Section: Related Literaturementioning

confidence: 99%

Intravenous immunoglobulin is a treatment option for refractory dermatomyositis in adult patients

Clapp

2018

Clin. Res. Pract.

View full text Add to dashboard Cite

show abstract

“…A phase IIb clinical trial evaluating the efficacy of abatacept in patients with refractory SAM demonstrated few serious adverse effects in approximately half of the patients' responses based on the criteria established by the International Myositis Assessment and Clinical Studies Group (IMACS) (B) [75].…”

Section: How Long Should Sam Patients Receive Immunosuppressive / Immmentioning

confidence: 99%

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

et al. 2019

View full text Add to dashboard Cite

Background: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM). Main body: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Ten recommendations were developed addressing the management and therapy of systemic autoimmune myopathies. Conclusions: Robust data to guide the therapeutic process are scarce. Although not proven effective in controlled clinical trials, glucocorticoid represents first-line drugs in the treatment of SAM. Intravenous immunoglobulin is considered in induction for refractory cases of SAM or when immunosuppressive drugs are contra-indicated. Consideration should be given to the early introduction of immunosuppressive drugs. There is no specific period determined for the suspension of glucocorticoid and immunosuppressive drugs when individually evaluating patients with SAM. A key component for treatment in an early rehabilitation program is the inclusion of strengthbuilding and aerobic exercises, in addition to a rigorous evaluation of these activities for remission of disease and the education of the patient and his/her caregivers.

show abstract

“…Se han usado en DM, PM y MCI como tercera línea. Estos actúan en múltiples niveles de la respuesta inflamatoria (Tabla 6) [66][67][68][69][70][71][72][73] conocerlos ya que han abierto una nueva ventana de manejo.…”

Section: Tratamientos Biológicosunclassified

Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo

et al. 2019

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies. A review Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different phenotypes, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.

show abstract

Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial

Abstract: In this pilot study, treatment of patients with DM and PM with abatacept resulted in lower disease activity in nearly half of the patients. In patients with repeat muscle biopsies, an increased frequency of Foxp3 Tregs suggests a positive effect of treatment in muscle tissue.

Cited by 115 publications

References 24 publications

Intravenous immunoglobulin is a treatment option for refractory dermatomyositis in adult patients

Intravenous immunoglobulin is a treatment option for refractory dermatomyositis in adult patients

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies

Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo

Contact Info

Product

Resources

About